Revenue segments as reported by the company.

Subscription services

Professional services and other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Sales and marketing

General and admin

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Veeva Systems

Veeva Systems, Inc. engages in the provision of industry cloud solutions for the global life sciences industry. Its solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. The firm's customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. Its regulated content management and collaboration solutions enable its customers to more efficiently manage regulated, content-centric processes across the enterprise. The company's customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. The company was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007, and is headquartered in Pleasanton, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Veeva Systems reports robust Q1 earnings, eyes growth opportunities

Veeva Systems delivered strong financial performance in Q1 2023, driven by robust execution and competitive wins. The company's focus on innovation, AI capabilities, and the transition to Vault CRM presents significant growth opportunities. However, challenges in the funding environment and customer migrations pose potential hurdles.

Veeva exceeds Q2 expectations, anticipates growth in clinical and data business

Veeva's Q2 performance exceeded expectations, leading to an increase in full-year guidance. The company's strengths lie in strong clinical activity, customer wins, and a focus on product excellence. However, challenges include migration costs, competitive landscape considerations, and marketing spend scrutiny. Veeva sees opportunities in M&A, minimal impact from R&D trends, and expansion of Veeva Link.

Veeva Systems surpasses Q3 expectations, eyes clinical data opportunity

Veeva Systems delivered a strong Q3 performance, with solid revenue and operating income. While facing challenges in billings and macroeconomic uncertainties, the company remains confident in its revenue target for fiscal year '25. The commitment from major enterprises and the potential in clinical data present significant opportunities for future growth.

Veeva Systems reports strong Q4 performance and forecasts $2.8B revenue

Veeva Systems showcases strong performance and strategic planning with revenue growth expectations of at least 15% in fiscal '24 and '25.
Positive feedback on product transitions and development, along with specialized sales teams, highlights market acceptance and innovation.
Challenges include short-term revenue impacts from timing-related issues and macro environment effects on customer spending.
Opportunities lie in revenue growth forecasts, product innovation, and market differentiation through new offerings and strategic deals.

Veeva Systems reports robust Q1 revenue growth and strategic focus

Veeva Systems' Q1 performance reflects strong revenue growth and a focus on customer-centric innovation. The company faces challenges in project scrutiny and competition but has opportunities in new product monetization and segment expansion.

Veeva Systems excels in Q2, eyes disciplined growth and innovation

Veeva Systems showcased robust financial performance, exceeding revenue and operating income targets, with a strong focus on customer success and product excellence.
While facing challenges such as migration costs and regulatory impacts, Veeva is well-positioned to leverage opportunities in disciplined M&A and product innovation.
The company's strategic growth initiatives, including Veeva Link expansion and CRM platform enhancements, aim to drive continued success and value for customers.

Veeva Systems posts solid Q3 results, eyes growth opportunities

Veeva Systems delivered a strong Q3 performance with solid revenue and operating income, showcasing financial stability and growth potential.
Despite challenges like trimmed billings and deal delays, Veeva remains confident in its fiscal year '25 revenue target, emphasizing strategic focus and operational efficiency.
The company's strengths in innovative products, strong partnerships, and global support ecosystem position it well for future growth and market leadership.
Opportunities in customer migration, AI integration, and market demand present avenues for Veeva to drive revenue growth and enhance its competitive positioning in the industry.

Veeva Systems excels in Q4 earnings, poised for strategic growth

Veeva Systems delivered strong financial performance in Q4 2024, showcasing revenue growth, operating income efficiency, and strategic product advancements.
The company's focus on innovation, customer success, and disciplined financial guidance positions it well for future growth and market leadership.
While facing challenges related to market uncertainties and operational considerations, Veeva remains resilient and poised to capitalize on opportunities for expansion and differentiation.
Overall, Veeva's Q4 earnings call highlights a balanced approach to growth, operational excellence, and strategic decision-making in a dynamic business environment.

Veeva Systems beats Q1 guidance, lowers full-year outlook amid challenges

Veeva Systems had a strong start to the year, exceeding Q1 guidance but lowering full-year revenue outlook due to macro challenges.
The company's performance in margin, client adoption, and innovation remains robust, with a focus on stability and predictability amidst industry challenges.
Challenges include AI disruption impacting plans, lower revenue guidance, and delays in funding benefits due to global conflicts and interest rate sensitivity.
Opportunities lie in new client bases, EDC deals progress, and the potential growth of Vault Basics and Link products in the market.

Veeva Systems excels in Q2, eyes strategic growth opportunities

Veeva Systems delivered a strong Q2 performance with revenue of $676 million and non-GAAP operating income of $280 million, driven by product expansions and customer wins.
The company's strengths lie in its comprehensive clinical suite, customer comfort with CRM solutions, and the importance of professional services for customer success.
Challenges include short-term billing growth constraints and the need for continuous product excellence, while opportunities exist in data architecture enhancement and upcoming Investor Day insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ResMed

Zoetis

The key to picking growth stocks right now is to look for companies whose earnings momentum and growth can withstand any market conditions. The post 3 Beaten-Down Growth Stocks With More Than 50% Upside Potential appeared first on InvestorPlace.

3 Beaten-Down Growth Stocks With More Than 50% Upside Potential

PLEASANTON, Calif., Feb. 23, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that leaders from Alexion, Merck & Co., Inc., Takeda, and Seagen will speak at the first-ever Veeva TMF Innovation Forum on March 10, 2022.

Industry Leaders to Come Together to Advance Digital Trials at Veeva TMF Innovation Forum

PLEASANTON, Calif., Feb. 23, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) has received broad recognition for its innovation, growth, and impact­––including its leading 'Work Anywhere' approach and pioneering a path as the first public company to convert to a Public Benefit Corporation (PBC).

Veeva Widely Recognized for Leadership and Innovation in Support of Customers and Employees

Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.

Veeva Systems (VEEV) Vault CDMS to Aid Idorsia's Clinical Trials

Starbucks

Shares of Veeva and Starbucks have been falling, but they may not stay down for long.

2 Unstoppable Stocks That Are On Sale Right Now

PLEASANTON, Calif., Feb. 15, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Idorsia Pharmaceuticals Ltd (SIX: IDIA) has expanded its use of Veeva Vault Clinical Suite applications to include Veeva Vault CDMS for electronic data capture (EDC) and coding.

Veeva Vault CDMS Selected by Idorsia to Modernize Clinical Data Management

PLEASANTON, Calif., Feb. 9, 2022 /PRNewswire/ -- Hundreds of pharmaceutical and biotech companies are standardizing content operations on Veeva Vault PromoMats to build a foundation for effective go-to-market and launch execution.

More than 300 Fast-Growing Biopharmas Set the Stage for Launch Success with Veeva Vault PromoMats

PLEASANTON, Calif., Feb. 1, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will announce financial results for its fourth quarter and full fiscal year, which ended January 31, 2022, after market close on March 2, 2022.

Veeva to Release Fiscal 2022 Fourth Quarter and Full Year Results on March 2, 2022

Advanced Micro Devices

NVIDIA

Nova Measuring Instruments

Universal Display

Silvergate Capital Corp

Capitalize on January's market weakness and buy high-growth stocks with high profit margins in February for long-term capital gains. The post 7 High-Growth Stocks With High Margins for Your February Buy List appeared first on InvestorPlace.

7 High-Growth Stocks With High Margins for Your February Buy List

DoorDash

Both companies are trading at 52-week lows, but there's reason for optimism ahead.

2 Growth Stocks Down 21% to 39% That Could Soar, According to Wall Street

Veeva Systems' (VEEV) Veeva Development Cloud will allow LYSARC to develop innovative lymphoma therapies or enhance current therapies.

Veeva Systems (VEEV)-LYSARC Partner to Advance Lymphoma Therapy

PLEASANTON, Calif., Jan. 25, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced the appointments of Tim Cabral, Priscilla Hung, Tina Hunt, and Marshall Mohr to its board of directors.

Veeva Appoints Four New Board Members

Clarivate Plc

We have identified names that look bearish and may present interesting investing opportunities on the short side. Using technical analysis of the charts of those stocks and appropriate recent actions, we have zeroed in on 2 names.

2 Stocks every investor should consider shorting this week

PLEASANTON, Calif., Jan. 20, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that the Lymphoma Academic Research Organization (LYSARC) selected Veeva Development Cloud to improve operational efficiency across its lymphoma therapy research.

LYSARC Partners with Veeva to Accelerate Innovation for Lymphoma Treatments

Teladoc

Twist Bioscience Corp

Business is booming for these life science businesses, but their stock prices have been slashed to bargain-basement prices.

3 Beaten-Down Life Science Stocks to Buy at a Discount

Domino's Pizza

HDFC Bank Limited

Taiwan Semiconductor Manufacturing

The GuruFocus business predictability rating ranks companies on a five-star scale, defining the more predictable companies as businesses whose revenue per share and Ebitda per share (or book value per share in case of financial stocks) have been growing steadily and who have produced a strong long-term performance of their stock prices.

4 Stock Picks for a Long-Term Approach

Veeva (VEEV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Veeva (VEEV) Stock Jumps 3.6%: Will It Continue to Soar?

CrowdStrike

The 3 Smartest Tech Stocks to Buy in 2022 and Beyond

Veeva (VEEV) reported earnings 30 days ago. What's next for the stock?

Why Is Veeva (VEEV) Down 0.9% Since Last Earnings Report?

Procore Technologies

Shopify

Customers rarely cut software spending once the tools are engrained within their business process, making SaaS stocks great investments.

My Favorite Software-as-a-Service Stocks for 2022

Microsoft

Palo Alto Networks

These tech stocks have economic moats and growth catalysts, but they're a bit expensive right now.

3 No-Brainer Stocks To Buy in a Market Correction

Veeva achieves quite high consumer satisfaction levels.

Veeva: Safe And Stable Growth Opportunity

Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Commercial Cloud business.

Veeva's (VEEV) Data Cloud to Aid PharmaEssentia's New Product

Veeva Systems' (VEEV) Veracity Logic buyout can help companies to simplify complex processes and speed up clinical trials.

Veeva Systems' (VEEV) Buyout to Bolster Clinical Offering

Veeva Systems (NYSE: VEEV) recently announced it has acquired Veracity Logic. These are the details.

News for Veeva Systems Stock (VEEV)